Related Experiment Video

Updated: Aug 17, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner

Jiajin Wu1, Chenkui Miao1, Yuhao Wang1

  • 1Department of Urology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, No. 300 Guangzhou Road, Nanjing, 210029, China.

Journal of Translational Medicine
|December 16, 2022
PubMed
Abstract

Insights

SPTBN1 is down-regulated in kidney cancer (ccRCC). Its loss promotes tumor growth by activating glycolysis, suggesting SPTBN1 as a potential therapeutic target for ccRCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Renal clear cell carcinoma (ccRCC) is the most common kidney cancer.
  • Identifying prognostic biomarkers is crucial for ccRCC management.
  • The role of SPTBN1 in ccRCC pathogenesis was previously unknown.

Purpose of the Study:

  • To investigate the biological function and molecular mechanism of SPTBN1 in ccRCC.
  • To determine the potential of SPTBN1 as a biomarker or therapeutic target for ccRCC.

Main Methods:

  • Utilized single-cell and bulk RNA sequencing, tissue microarrays, qPCR, and Western blotting to assess SPTBN1 expression.
  • Generated and analyzed ccRCC cell line models with SPTBN1 gain or loss of function.
  • Conducted in vitro and in vivo assays, along with molecular experiments (Actinomycin D, RIP, inhibitor studies, rescue experiments) to elucidate mechanisms.

Main Results:

  • SPTBN1 expression was found to be significantly downregulated in ccRCC tissues.
  • Knockdown of SPTBN1 promoted ccRCC cell proliferation and tumor growth in vitro and in vivo.
  • Overexpression of SPTBN1 inhibited ccRCC progression.
  • SPTBN1 regulates ccRCC progression through the GPT2-dependent glycolysis pathway.
  • SPTBN1, as an RNA-binding protein, controls GPT2 mRNA stability, with GPT2 expression inversely correlated to SPTBN1.

Conclusions:

  • SPTBN1 is significantly downregulated in ccRCC and acts as a tumor suppressor.
  • SPTBN1 knockdown promotes ccRCC progression by activating GPT2-dependent glycolysis.
  • SPTBN1 represents a potential therapeutic target for ccRCC treatment.
Keywords:
BiomarkerGPT2GlycolysisMetabolic reprogrammingPrognosisRenal clear cell carcinomaSPTBN1

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.0K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K